5 Newly Undervalued Stocks for the Month

Updated for February 2025: Tate & Lyle and Unilever are among the stocks in undervalued territory.

Bella Albrecht 19 February, 2025 | 10:44AM
Facebook Twitter LinkedIn

Photo collage illustration of graph elements and sterling coins floating.

Each month, we screen the Europe-listed stocks under Morningstar’s coverage for newly undervalued names.

Over the past month, five stocks saw their Morningstar Ratings change to 4 stars, while another one dropped into 5-star territory. Stocks rated 3 stars are fairly valued according to Morningstar analysts, while those rated 1 or 2 stars are considered overvalued.

The one new 5-star European stock is:

• Tate & Lyle TATE

The five new 4-star European stocks, ordered by market-cap, are:

• Equinor EQNR

• Swedish Orphan Biovitrum SOBI

• Unilever ULVR

• Safran Group SAF

• Bureau Veritas BVI

All returns in this article are reported in the stock’s base currency and all data is sourced from Morningstar Direct.

Newly Undervalued Stocks as of Feb. 18

The Morningstar Europe Index rose 6.42% over the past month, leaving the overall European stock market slightly overvalued, hovering at a 2% premium to its fair value estimate on a cap-weighted basis.

Of the 255 Europe-listed stocks covered by Morningstar analysts:

• 42% are undervalued, 38% are fairly valued, and 19% are overvalued.

• Five are newly undervalued.

• 12 are newly overvalued.

• One moved from a 4-star rating to a 5-star rating.

• Four moved from a 5-star rating to a 4-star rating.

• Among the newly undervalued stocks, none jumped from a 3-star rating to a 5-star rating.

• 20 are no longer undervalued.

Morningstar analysts assign every stock under their coverage a fair value estimate, which is an intrinsic measure of the stock’s worth, and an Uncertainty Rating, which captures the range of potential outcomes for that estimate. A higher Uncertainty Rating equates to a larger range of prices considered fairly valued.

These two metrics and the stock’s current price, are used to determine its Morningstar Rating.

Distribution of Star Ratings for Europe-Listed Stocks

Source: Morningstar Direct. Data as of Feb. 18, 2025.

Metrics for this Month’s New 5-Star Stock

Tate & Lyle TATE

• Morningstar Rating: ★★★★★

• One-Month Return: -14.98%

Packaged foods company Tate & Lyle has lost 24.75% over the past three months and 7.01% over the past year. The mid-core stock has a narrow economic moat. Tate & Lyle is trading at a 38% discount to its fair value estimate of GBX 900, with an Uncertainty Rating of Medium.

Metrics for this Month’s New 4-Star Stocks

Equinor EQNR

• Morningstar Rating: ★★★★

• One-Month Return: -11.17%

Oil and gas firm Equinor has lost 3.12% over the past three months and gained 3.22% over the past year. The large-value stock has no economic moat. Equinor is trading at a 21% discount to its fair value estimate of NOK 320, with an Uncertainty Rating of High.

Swedish Orphan Biovitrum SOBI

• Morningstar Rating: ★★★★

• One-Month Return: -3.63%

Drug manufacturer Swedish Orphan Biovitrum has climbed 6.20% over the past three months and 25.31% over the past year. The fair value estimate for Swedish Orphan Biovitrum rose to SEK 357 from SEK 343 during the month. It ended the month trading at an 11% discount to its new fair value estimate, with an Uncertainty Rating of Medium. Swedish Orphan Biovitrum is a mid-growth company with a narrow economic moat.

Unilever ULVR

• Morningstar Rating: ★★★★

• One-Month Return: -5.38%

Household and personal products company Unilever is down 4.72% over the past three months and up 11.36% over the past year. The fair value estimate for Unilever rose to GBX 4,750 from GBX 4,380 during the month. It ended the month trading at a 9% discount to its new fair value estimate, with an Uncertainty Rating of Low. The large-core stock has a wide economic moat.

Safran Group SAF

• Morningstar Rating: ★★★★

• One-Month Return: 10.51%

Aerospace and defense company Safran has gained 15.12% over the past three months and 35.13% over the past year. The large-growth stock has a wide economic moat. The fair value estimate for Safran rose to EUR 286 from EUR 200 during the month. It ended the month trading at a 12% discount to its new fair value estimate, with an Uncertainty Rating of Medium.

Bureau Veritas BVI

• Morningstar Rating: ★★★★

• One-Month Return: 1.98%

Consulting firm Bureau Veritas is up 9.18% over the past three months and 26.37% over the past year. The fair value estimate for Bureau Veritas rose to EUR 40 from EUR 30 during the month. It ended the month trading at a 23% discount to its new fair value estimate, with an Uncertainty Rating of Medium. The mid-core stock has a wide economic moat.


This article was generated with the help of automation and reviewed by Morningstar editors. Learn more about Morningstar’s use of automation.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar's editorial policies.

TAGS

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Bella Albrecht  is associate data journalist at Morningstar

© Copyright 2025 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures